OXFD
NASDAQOxford Immunotec Global PLC
Oxford Immunotec Global PLC (OXFD) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. There were no new wire items for OXFD in the last 30 days. The most recent was published May 7, 2021.
Latest news
25 items- 13D/GSEC Form SC 13G filed by Oxford Immunotec Global PLCSC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)
- SECSEC Form 15-12B filed by Oxford Immunotec Global PLC15-12B - Oxford Immunotec Global PLC (0001586049) (Filer)
- SECSEC Form S-8 POS filedS-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)
- INSIDERSEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: R. Mark Klausner disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: Patricia Randall disposed to the issuer $611,710 worth of Ordinary Shares (27,805 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: Louise Janet Kidd disposed to the issuer $246,554 worth of Ordinary Shares (11,207 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: J Patrick Balthrop disposed to the issuer $177,782 worth of Ordinary Shares (8,081 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: Scott Andrew Walton disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: Peter Wrighton-Smith disposed to the issuer $8,804,950 worth of Ordinary Shares (400,225 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- INSIDERSEC Form 4: Asbury Ronald Andrews disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- SECSEC Form S-8 POS filedS-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)
- INSIDERSEC Form 4: R James Tobin disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units4 - Oxford Immunotec Global PLC (0001586049) (Issuer)
- 13D/GSEC Form SC 13G filedSC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)
- SECSEC Form 8-K filed8-K - Oxford Immunotec Global PLC (0001586049) (Filer)
- SECSEC Form 25-NSE filed25-NSE - Oxford Immunotec Global PLC (0001586049) (Subject)
- PROxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 InfectionOXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. T-SPOT®.COVID, a Test from Oxford Immunotec Global PLC for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infe
- SECSEC Form 8-K/A filed8-K/A - Oxford Immunotec Global PLC (0001586049) (Filer)
- SECSEC Form 8-K filed8-K - Oxford Immunotec Global PLC (0001586049) (Filer)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - Oxford Immunotec Global PLC (0001586049) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - Oxford Immunotec Global PLC (0001586049) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - Oxford Immunotec Global PLC (0001586049) (Subject)
- 13D/GSEC Form SC 13G filedSC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)
OXFD FAQ
6 questionsWhat is the latest news on OXFD?
Quantisnow has not tracked any new filings, ratings or press releases for OXFD in the last 30 days. The most recent wire item was published on May 7, 2021.Where does OXFD stock trade?
Oxford Immunotec Global PLC (OXFD) is listed on NASDAQ.What sector and industry is OXFD in?
Oxford Immunotec Global PLC operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Oxford Immunotec Global PLC go public?
Oxford Immunotec Global PLC (OXFD) completed its IPO in 2013.What companies are similar to OXFD?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), ORKA (Oruka Therapeutics Inc.), LNTH (Lantheus Holdings Inc.), NEOG (Neogen Corporation), CLDX (Celldex Therapeutics Inc.). Compare OXFD side-by-side with any of them on Quantisnow.How can I track OXFD on Quantisnow?
Quantisnow aggregates Oxford Immunotec Global PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OXFD to receive live email and push alerts on every new disclosure.